Kimberly Gold Blumenthal, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Hypersensitivity | 96 | 2024 | 923 | 23.630 |
Why?
|
Penicillins | 49 | 2024 | 406 | 14.810 |
Why?
|
Anaphylaxis | 28 | 2024 | 758 | 7.270 |
Why?
|
beta-Lactams | 16 | 2023 | 158 | 6.450 |
Why?
|
Hypersensitivity | 29 | 2024 | 1172 | 6.110 |
Why?
|
Anti-Bacterial Agents | 59 | 2024 | 7477 | 5.720 |
Why?
|
Skin Tests | 31 | 2024 | 639 | 3.500 |
Why?
|
Eosinophilia | 7 | 2024 | 556 | 2.590 |
Why?
|
Vancomycin | 8 | 2022 | 506 | 2.360 |
Why?
|
Cephalosporins | 9 | 2023 | 200 | 2.290 |
Why?
|
Urticaria | 4 | 2022 | 151 | 2.230 |
Why?
|
Allergy and Immunology | 8 | 2024 | 175 | 2.070 |
Why?
|
Hypersensitivity, Immediate | 5 | 2023 | 349 | 1.730 |
Why?
|
Electronic Health Records | 27 | 2024 | 4887 | 1.720 |
Why?
|
Vaccines | 7 | 2024 | 842 | 1.710 |
Why?
|
Desensitization, Immunologic | 9 | 2024 | 558 | 1.480 |
Why?
|
Cefazolin | 5 | 2024 | 95 | 1.440 |
Why?
|
Allergens | 17 | 2022 | 1443 | 1.390 |
Why?
|
Exanthema | 5 | 2023 | 503 | 1.280 |
Why?
|
Soft Tissue Infections | 2 | 2021 | 168 | 1.220 |
Why?
|
Physicians, Women | 3 | 2023 | 517 | 1.090 |
Why?
|
Vaccination | 13 | 2024 | 3437 | 1.080 |
Why?
|
Drug Eruptions | 5 | 2024 | 335 | 1.050 |
Why?
|
Humans | 180 | 2024 | 768166 | 1.000 |
Why?
|
Documentation | 13 | 2024 | 917 | 0.980 |
Why?
|
Angioedema | 3 | 2022 | 184 | 0.870 |
Why?
|
Staphylococcal Infections | 3 | 2018 | 1398 | 0.870 |
Why?
|
Immunization, Secondary | 2 | 2024 | 373 | 0.840 |
Why?
|
Immunologic Tests | 3 | 2019 | 104 | 0.830 |
Why?
|
Vaccines, Synthetic | 4 | 2022 | 622 | 0.830 |
Why?
|
Inpatients | 10 | 2023 | 2566 | 0.800 |
Why?
|
Surgical Wound Infection | 4 | 2021 | 1546 | 0.750 |
Why?
|
Skin Diseases, Bacterial | 1 | 2021 | 65 | 0.740 |
Why?
|
Antibiotic Prophylaxis | 5 | 2024 | 640 | 0.740 |
Why?
|
Stevens-Johnson Syndrome | 3 | 2024 | 232 | 0.690 |
Why?
|
Physicians | 3 | 2022 | 4598 | 0.690 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 704 | 0.690 |
Why?
|
Erythema | 1 | 2021 | 261 | 0.660 |
Why?
|
Electronics, Medical | 1 | 2019 | 72 | 0.650 |
Why?
|
Viral Vaccines | 2 | 2022 | 596 | 0.640 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 4 | 2018 | 2271 | 0.630 |
Why?
|
Bacteremia | 2 | 2016 | 986 | 0.620 |
Why?
|
Food Hypersensitivity | 3 | 2022 | 734 | 0.600 |
Why?
|
RNA, Messenger | 11 | 2022 | 12800 | 0.590 |
Why?
|
Methicillin | 2 | 2016 | 62 | 0.580 |
Why?
|
Female | 74 | 2024 | 397192 | 0.570 |
Why?
|
Terminology as Topic | 3 | 2024 | 1542 | 0.550 |
Why?
|
Practice Guidelines as Topic | 7 | 2019 | 7454 | 0.530 |
Why?
|
Male | 64 | 2024 | 364719 | 0.510 |
Why?
|
Middle Aged | 49 | 2024 | 223492 | 0.510 |
Why?
|
Decision Making, Computer-Assisted | 1 | 2016 | 146 | 0.500 |
Why?
|
Decision Support Systems, Clinical | 4 | 2020 | 1178 | 0.500 |
Why?
|
Costs and Cost Analysis | 2 | 2020 | 1667 | 0.500 |
Why?
|
Diagnostic Tests, Routine | 2 | 2019 | 789 | 0.490 |
Why?
|
Drug Prescriptions | 2 | 2015 | 1668 | 0.490 |
Why?
|
Cross Reactions | 4 | 2019 | 828 | 0.460 |
Why?
|
Nafcillin | 1 | 2014 | 23 | 0.460 |
Why?
|
Faculty, Medical | 2 | 2020 | 1226 | 0.460 |
Why?
|
Skin Diseases | 2 | 2021 | 1085 | 0.450 |
Why?
|
Immunoglobulin E | 7 | 2024 | 1506 | 0.450 |
Why?
|
Consensus | 4 | 2024 | 3212 | 0.440 |
Why?
|
Asthma | 5 | 2024 | 6291 | 0.420 |
Why?
|
Biological Products | 1 | 2022 | 948 | 0.420 |
Why?
|
Adult | 40 | 2024 | 223646 | 0.420 |
Why?
|
Retrospective Studies | 23 | 2024 | 81762 | 0.420 |
Why?
|
Qualitative Research | 1 | 2024 | 3140 | 0.410 |
Why?
|
United States | 24 | 2024 | 73039 | 0.410 |
Why?
|
Women's Health | 1 | 2022 | 2082 | 0.410 |
Why?
|
Aged | 35 | 2024 | 171504 | 0.410 |
Why?
|
Schools, Medical | 1 | 2019 | 883 | 0.410 |
Why?
|
Quality Improvement | 3 | 2022 | 3857 | 0.400 |
Why?
|
Anesthesia | 2 | 2020 | 1596 | 0.380 |
Why?
|
Outpatients | 5 | 2023 | 1600 | 0.380 |
Why?
|
Boston | 7 | 2021 | 9374 | 0.380 |
Why?
|
Influenza Vaccines | 1 | 2019 | 781 | 0.370 |
Why?
|
Clostridium Infections | 1 | 2018 | 562 | 0.370 |
Why?
|
Education | 1 | 2014 | 533 | 0.370 |
Why?
|
Preoperative Care | 1 | 2020 | 2258 | 0.360 |
Why?
|
Drug Utilization | 1 | 2017 | 1189 | 0.360 |
Why?
|
Cross-Sectional Studies | 12 | 2024 | 26379 | 0.350 |
Why?
|
Academic Medical Centers | 2 | 2020 | 2784 | 0.350 |
Why?
|
Referral and Consultation | 2 | 2023 | 3620 | 0.350 |
Why?
|
Pharmaceutical Preparations | 5 | 2020 | 1088 | 0.350 |
Why?
|
Population Surveillance | 2 | 2019 | 2596 | 0.330 |
Why?
|
Pneumonia | 1 | 2021 | 2163 | 0.330 |
Why?
|
Sex Factors | 6 | 2024 | 10632 | 0.300 |
Why?
|
Staphylococcus aureus | 1 | 2016 | 1430 | 0.300 |
Why?
|
Phenotype | 2 | 2023 | 16726 | 0.300 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2185 | 0.290 |
Why?
|
Data Collection | 1 | 2017 | 3327 | 0.290 |
Why?
|
Cohort Studies | 12 | 2021 | 41754 | 0.280 |
Why?
|
Health Expenditures | 1 | 2020 | 2389 | 0.280 |
Why?
|
Amoxicillin | 2 | 2019 | 182 | 0.280 |
Why?
|
Registries | 7 | 2024 | 8375 | 0.250 |
Why?
|
Self Report | 3 | 2024 | 3773 | 0.240 |
Why?
|
Comorbidity | 2 | 2018 | 10590 | 0.230 |
Why?
|
Delivery of Health Care | 7 | 2022 | 5367 | 0.230 |
Why?
|
Risk | 5 | 2019 | 9613 | 0.230 |
Why?
|
Ambulatory Care | 3 | 2023 | 2783 | 0.220 |
Why?
|
Anxiety | 1 | 2018 | 4672 | 0.220 |
Why?
|
Risk Factors | 11 | 2024 | 74944 | 0.210 |
Why?
|
Latex | 1 | 2022 | 49 | 0.210 |
Why?
|
Dietary Supplements | 1 | 2016 | 3445 | 0.210 |
Why?
|
Incidence | 6 | 2021 | 21538 | 0.210 |
Why?
|
Rosaniline Dyes | 1 | 2021 | 50 | 0.190 |
Why?
|
Prospective Studies | 9 | 2023 | 54926 | 0.190 |
Why?
|
Telemedicine | 1 | 2019 | 3109 | 0.190 |
Why?
|
Dermatology | 2 | 2021 | 905 | 0.190 |
Why?
|
Adverse Drug Reaction Reporting Systems | 2 | 2022 | 496 | 0.190 |
Why?
|
Chickenpox | 1 | 2021 | 95 | 0.180 |
Why?
|
Immunoglobulin G | 3 | 2022 | 4568 | 0.180 |
Why?
|
Syndrome | 2 | 2021 | 3272 | 0.180 |
Why?
|
IgG Deficiency | 1 | 2020 | 28 | 0.180 |
Why?
|
Prevalence | 7 | 2018 | 15869 | 0.170 |
Why?
|
Aged, 80 and over | 9 | 2021 | 59629 | 0.170 |
Why?
|
Vocabulary, Controlled | 2 | 2018 | 170 | 0.170 |
Why?
|
Immunoglobulin Isotypes | 1 | 2020 | 158 | 0.170 |
Why?
|
Texas | 1 | 2020 | 410 | 0.160 |
Why?
|
Cross Infection | 2 | 2018 | 1426 | 0.160 |
Why?
|
Herpes Zoster | 1 | 2021 | 252 | 0.160 |
Why?
|
Personnel, Hospital | 1 | 2021 | 285 | 0.160 |
Why?
|
Natural Language Processing | 4 | 2021 | 1203 | 0.160 |
Why?
|
Depression | 1 | 2018 | 8230 | 0.150 |
Why?
|
Odds Ratio | 3 | 2020 | 9669 | 0.150 |
Why?
|
Career Mobility | 1 | 2020 | 262 | 0.150 |
Why?
|
Immunity, Humoral | 1 | 2022 | 610 | 0.150 |
Why?
|
Excipients | 3 | 2023 | 96 | 0.150 |
Why?
|
Herpes Simplex | 1 | 2021 | 470 | 0.150 |
Why?
|
Nausea | 1 | 2021 | 682 | 0.150 |
Why?
|
Community Health Planning | 1 | 2018 | 164 | 0.150 |
Why?
|
Length of Stay | 2 | 2024 | 6498 | 0.150 |
Why?
|
Clindamycin | 1 | 2018 | 138 | 0.140 |
Why?
|
Expert Testimony | 1 | 2018 | 266 | 0.140 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2021 | 737 | 0.140 |
Why?
|
Decision Support Techniques | 2 | 2017 | 2008 | 0.140 |
Why?
|
Shock, Cardiogenic | 1 | 2022 | 711 | 0.140 |
Why?
|
Pregnancy | 5 | 2023 | 30256 | 0.140 |
Why?
|
beta-Lactamases | 1 | 2018 | 307 | 0.130 |
Why?
|
Allopurinol | 1 | 2018 | 202 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 879 | 0.130 |
Why?
|
Hospitals, General | 1 | 2021 | 809 | 0.130 |
Why?
|
Gout Suppressants | 1 | 2018 | 176 | 0.130 |
Why?
|
Infusions, Intravenous | 1 | 2021 | 2230 | 0.130 |
Why?
|
International Classification of Diseases | 2 | 2019 | 937 | 0.130 |
Why?
|
Drug Resistance, Microbial | 1 | 2018 | 830 | 0.130 |
Why?
|
Carboplatin | 1 | 2018 | 797 | 0.130 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2020 | 709 | 0.130 |
Why?
|
Vascular Grafting | 1 | 2017 | 163 | 0.130 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2016 | 83 | 0.120 |
Why?
|
Computer Simulation | 2 | 2020 | 6283 | 0.120 |
Why?
|
Antineoplastic Agents | 4 | 2024 | 13676 | 0.120 |
Why?
|
Polyethylene Glycols | 1 | 2021 | 1196 | 0.120 |
Why?
|
Hypotension | 1 | 2021 | 888 | 0.120 |
Why?
|
Massachusetts | 3 | 2018 | 8890 | 0.120 |
Why?
|
Risk Adjustment | 1 | 2018 | 599 | 0.120 |
Why?
|
Nephritis, Interstitial | 1 | 2016 | 158 | 0.120 |
Why?
|
Policy | 1 | 2018 | 513 | 0.120 |
Why?
|
Case-Control Studies | 2 | 2024 | 22291 | 0.120 |
Why?
|
Blood Circulation | 1 | 2015 | 248 | 0.110 |
Why?
|
Paclitaxel | 1 | 2021 | 1733 | 0.110 |
Why?
|
Breast Neoplasms | 1 | 2021 | 21206 | 0.110 |
Why?
|
Data Mining | 1 | 2019 | 563 | 0.110 |
Why?
|
Congresses as Topic | 1 | 2018 | 812 | 0.110 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12543 | 0.110 |
Why?
|
Databases as Topic | 1 | 2015 | 472 | 0.110 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 951 | 0.110 |
Why?
|
Hospitalization | 4 | 2021 | 10840 | 0.110 |
Why?
|
Survivors | 1 | 2023 | 2381 | 0.100 |
Why?
|
Internal Medicine | 1 | 2020 | 1064 | 0.100 |
Why?
|
Cisplatin | 1 | 2018 | 1660 | 0.100 |
Why?
|
Standard of Care | 1 | 2017 | 568 | 0.100 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1673 | 0.100 |
Why?
|
International Cooperation | 1 | 2018 | 1436 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2024 | 1885 | 0.100 |
Why?
|
Professional Practice | 1 | 2014 | 314 | 0.100 |
Why?
|
Infusions, Parenteral | 1 | 2012 | 396 | 0.100 |
Why?
|
Medication Adherence | 1 | 2023 | 2187 | 0.100 |
Why?
|
Cesarean Section | 1 | 2020 | 1425 | 0.100 |
Why?
|
Herpesvirus 6, Human | 1 | 2012 | 98 | 0.090 |
Why?
|
Nephritis | 1 | 2012 | 147 | 0.090 |
Why?
|
Surgical Procedures, Operative | 1 | 2022 | 1932 | 0.090 |
Why?
|
Cardiovascular Agents | 1 | 2017 | 849 | 0.090 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 1642 | 0.090 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2337 | 0.090 |
Why?
|
Medical Order Entry Systems | 1 | 2015 | 524 | 0.090 |
Why?
|
Lymphatic Diseases | 1 | 2012 | 319 | 0.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 1515 | 0.090 |
Why?
|
Eosinophils | 1 | 2015 | 952 | 0.090 |
Why?
|
Hepatitis | 1 | 2012 | 227 | 0.090 |
Why?
|
Logistic Models | 3 | 2020 | 13290 | 0.080 |
Why?
|
Microbial Sensitivity Tests | 1 | 2016 | 1967 | 0.080 |
Why?
|
Tachycardia | 1 | 2012 | 599 | 0.080 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2726 | 0.080 |
Why?
|
Education, Medical | 1 | 2021 | 1742 | 0.080 |
Why?
|
Physician-Patient Relations | 1 | 2022 | 3269 | 0.080 |
Why?
|
Patient Selection | 1 | 2021 | 4260 | 0.080 |
Why?
|
Ischemia | 1 | 2017 | 1900 | 0.080 |
Why?
|
Anticonvulsants | 1 | 2018 | 1923 | 0.080 |
Why?
|
Sulfonamides | 1 | 2018 | 1982 | 0.080 |
Why?
|
Young Adult | 4 | 2019 | 60066 | 0.080 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1206 | 0.080 |
Why?
|
Risk Assessment | 5 | 2024 | 24315 | 0.070 |
Why?
|
Mortality | 1 | 2019 | 2911 | 0.070 |
Why?
|
Perioperative Care | 1 | 2015 | 1043 | 0.070 |
Why?
|
Systematized Nomenclature of Medicine | 2 | 2018 | 35 | 0.070 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2018 | 1417 | 0.070 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2018 | 1389 | 0.070 |
Why?
|
Public Health | 1 | 2020 | 2679 | 0.070 |
Why?
|
Curriculum | 1 | 2020 | 3782 | 0.070 |
Why?
|
Age Factors | 2 | 2021 | 18412 | 0.070 |
Why?
|
Perioperative Period | 2 | 2019 | 253 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2665 | 0.070 |
Why?
|
Peripheral Arterial Disease | 1 | 2017 | 1304 | 0.060 |
Why?
|
Child | 5 | 2023 | 80917 | 0.060 |
Why?
|
Health Care Costs | 1 | 2018 | 3239 | 0.060 |
Why?
|
Europe | 3 | 2021 | 3436 | 0.060 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15948 | 0.060 |
Why?
|
Immunologic Factors | 1 | 2014 | 1596 | 0.060 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3683 | 0.060 |
Why?
|
Acute Generalized Exanthematous Pustulosis | 1 | 2024 | 14 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3231 | 0.060 |
Why?
|
Fever | 1 | 2012 | 1614 | 0.060 |
Why?
|
Time Factors | 3 | 2021 | 40218 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14783 | 0.060 |
Why?
|
Aztreonam | 1 | 2023 | 10 | 0.050 |
Why?
|
Endovascular Procedures | 1 | 2017 | 2216 | 0.050 |
Why?
|
Disease Management | 1 | 2014 | 2536 | 0.050 |
Why?
|
Algorithms | 2 | 2020 | 14164 | 0.050 |
Why?
|
Polysorbates | 1 | 2022 | 46 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 13490 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8748 | 0.050 |
Why?
|
Herpesvirus 3, Human | 1 | 2021 | 159 | 0.040 |
Why?
|
Models, Statistical | 1 | 2015 | 5107 | 0.040 |
Why?
|
Delphi Technique | 1 | 2024 | 891 | 0.040 |
Why?
|
Hospitals | 1 | 2023 | 3886 | 0.040 |
Why?
|
Serum Sickness | 1 | 2019 | 26 | 0.040 |
Why?
|
Basophil Degranulation Test | 1 | 2019 | 20 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39348 | 0.040 |
Why?
|
Feedback | 1 | 2023 | 799 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9495 | 0.040 |
Why?
|
Simplexvirus | 1 | 2021 | 805 | 0.040 |
Why?
|
Infant | 2 | 2019 | 36535 | 0.040 |
Why?
|
Radioallergosorbent Test | 1 | 2017 | 19 | 0.040 |
Why?
|
Hypersensitivity, Delayed | 1 | 2018 | 491 | 0.040 |
Why?
|
Postoperative Period | 1 | 2022 | 1826 | 0.040 |
Why?
|
Shellfish | 1 | 2017 | 37 | 0.040 |
Why?
|
Tryptases | 1 | 2018 | 176 | 0.040 |
Why?
|
Child, Preschool | 2 | 2019 | 42669 | 0.030 |
Why?
|
Motion Therapy, Continuous Passive | 1 | 1996 | 11 | 0.030 |
Why?
|
Dermatitis, Atopic | 1 | 2024 | 737 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 13014 | 0.030 |
Why?
|
Dermatitis | 1 | 2018 | 203 | 0.030 |
Why?
|
Air Pollution, Indoor | 2 | 2001 | 931 | 0.030 |
Why?
|
North America | 1 | 2019 | 1289 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 598 | 0.030 |
Why?
|
Decision Trees | 1 | 2017 | 508 | 0.030 |
Why?
|
Th2 Cells | 1 | 2001 | 1078 | 0.030 |
Why?
|
Adolescent | 4 | 2019 | 89169 | 0.030 |
Why?
|
Finger Injuries | 1 | 1996 | 145 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2359 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10760 | 0.030 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2015 | 198 | 0.030 |
Why?
|
Markov Chains | 1 | 2017 | 979 | 0.030 |
Why?
|
Glycoproteins | 1 | 2001 | 2202 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 3814 | 0.030 |
Why?
|
Treatment Outcome | 3 | 2017 | 65371 | 0.030 |
Why?
|
Tendon Injuries | 1 | 1996 | 329 | 0.030 |
Why?
|
ROC Curve | 1 | 2020 | 3628 | 0.030 |
Why?
|
Neoplasms | 1 | 2021 | 22371 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 2011 | 0.020 |
Why?
|
Databases, Factual | 2 | 2018 | 8080 | 0.020 |
Why?
|
Leadership | 1 | 2020 | 1397 | 0.020 |
Why?
|
Drug Interactions | 1 | 2015 | 1419 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1741 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2020 | 20227 | 0.020 |
Why?
|
Postoperative Care | 1 | 1996 | 1480 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2017 | 15454 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2015 | 1407 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2020 | 3573 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 5536 | 0.020 |
Why?
|
Inhalation Exposure | 2 | 2001 | 432 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2020 | 12077 | 0.020 |
Why?
|
Stents | 1 | 2017 | 3195 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7852 | 0.010 |
Why?
|
Critical Illness | 1 | 2017 | 2756 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7951 | 0.010 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2001 | 361 | 0.010 |
Why?
|
Models, Immunological | 1 | 2001 | 518 | 0.010 |
Why?
|
Australia | 1 | 2000 | 1265 | 0.010 |
Why?
|
Respiratory Sounds | 1 | 2001 | 702 | 0.010 |
Why?
|
Thumb | 1 | 1996 | 232 | 0.010 |
Why?
|
Maternal Exposure | 1 | 2000 | 1096 | 0.010 |
Why?
|
Life Style | 1 | 2001 | 3932 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1996 | 8542 | 0.000 |
Why?
|
Infant, Newborn | 1 | 2000 | 26422 | 0.000 |
Why?
|